StockNews.com Initiates Coverage on Agile Therapeutics (NASDAQ:AGRX)

StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRXGet Free Report) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group restated a “hold” rating on shares of Agile Therapeutics in a research report on Monday, March 18th.

View Our Latest Stock Analysis on Agile Therapeutics

Agile Therapeutics Price Performance

Shares of NASDAQ:AGRX opened at $0.36 on Thursday. The firm has a market capitalization of $2.48 million, a PE ratio of -0.10 and a beta of 1.25. Agile Therapeutics has a twelve month low of $0.20 and a twelve month high of $4.06. The company has a 50-day moving average price of $0.38 and a two-hundred day moving average price of $1.13.

Agile Therapeutics (NASDAQ:AGRXGet Free Report) last released its quarterly earnings data on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter. The firm had revenue of $5.72 million for the quarter.

Institutional Investors Weigh In On Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC raised its stake in shares of Agile Therapeutics, Inc. (NASDAQ:AGRXFree Report) by 10.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the quarter. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 10.92% of the company’s stock.

About Agile Therapeutics

(Get Free Report)

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

See Also

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.